These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 36203787)

  • 41. Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial.
    Buynak R; Rappaport SA; Rod K; Arsenault P; Heisig F; Rauschkolb C; Etropolski M
    Clin Ther; 2015 Nov; 37(11):2420-38. PubMed ID: 26428249
    [TBL] [Abstract][Full Text] [Related]  

  • 42. IMI2-PainCare-BioPain-RCT3: a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by electroencephalography (EEG).
    Mouraux A; Bloms-Funke P; Boesl I; Caspani O; Chapman SC; Di Stefano G; Finnerup NB; Garcia-Larrea L; Goetz M; Kostenko A; Pelz B; Pogatzki-Zahn E; Schubart K; Stouffs A; Truini A; Tracey I; Troconiz IF; Van Niel J; Vela JM; Vincent K; Vollert J; Wanigasekera V; Wittayer M; Phillips KG; Treede RD
    Trials; 2021 Jun; 22(1):404. PubMed ID: 34140041
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis.
    Wu J; Wu H; Wang Y; Chen Y; Guo B; Cao G; Wu X; Yu J; Wu J; Zhu D; Guo Y; Yuan H; Hu F; Zhang J
    Clin Ther; 2019 Jun; 41(6):1164-1174.e4. PubMed ID: 31126694
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A system of equations to approximate the pharmacokinetic parameters of lacosamide at steady state from one plasma sample.
    Cawello W; Schäfer C
    Epilepsy Res; 2014 Aug; 108(6):1068-75. PubMed ID: 24893832
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers.
    Jones A; Wang-Smith L; Pham T; Laliberte K
    J Cardiovasc Pharmacol; 2014 Mar; 63(3):227-32. PubMed ID: 24603117
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tapentadol Prolonged Release for Long-Term Treatment of Pain in Children.
    Howard RF; Radic T; Sohns M; Eerdekens M; Waßmuth A
    J Pain Res; 2020; 13():3157-3170. PubMed ID: 33311995
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Post hoc analyses of data from a 90-day clinical trial evaluating the tolerability and efficacy of tapentadol immediate release and oxycodone immediate release for the relief of moderate to severe pain in elderly and nonelderly patients.
    Vorsanger G; Xiang J; Biondi D; Upmalis D; Delfgaauw J; Allard R; Moskovitz B
    Pain Res Manag; 2011; 16(4):245-51. PubMed ID: 22059194
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An Open-Label Study Evaluating the Pharmacokinetics and Safety of Diclofenac Potassium for Oral Solution for the Acute Treatment of MWA or MWoA in Pediatric Participants.
    McVige JW; Hogan RM; Shanahan CM; Amend DL; Ferger SM
    Headache; 2020 Oct; 60(9):1939-1946. PubMed ID: 32767766
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics, Safety, and Tolerability of SHP465 Mixed Amphetamine Salts After Administration of Multiple Daily Doses in Children Aged 4-5 Years with Attention-Deficit/Hyperactivity Disorder.
    Ilic K; Kugler AR; Yan B; McNamara N
    CNS Drugs; 2022 Jan; 36(1):71-81. PubMed ID: 34826114
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combatting pain after orthopedic/trauma surgery- perioperative oral extended-release tapentadol vs. extended-release oxycodone/naloxone.
    Haeseler G; Schaefers D; Prison N; Ahrens J; Liu X; Karch A
    BMC Anesthesiol; 2017 Jul; 17(1):91. PubMed ID: 28693439
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Driving Ability in Patients with Severe Chronic Low Back or Osteoarthritis Knee Pain on Stable Treatment with Tapentadol Prolonged Release: A Multicenter, Open-label, Phase 3b Trial.
    Sabatowski R; Scharnagel R; Gyllensvärd A; Steigerwald I
    Pain Ther; 2014 Jun; 3(1):17-29. PubMed ID: 25135385
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Unique pharmacology of tapentadol for treating acute and chronic pain.
    Knezevic NN; Tverdohleb T; Knezevic I; Candido KD
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1475-92. PubMed ID: 26215077
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients.
    Yu JK; Iorio A; Edginton AN
    Thromb Res; 2020 Dec; 196():550-558. PubMed ID: 33157394
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain.
    Kress HG; Koch ED; Kosturski H; Steup A; Karcher K; Lange B; Dogan C; Etropolski MS; Eerdekens M
    Pain Physician; 2014; 17(4):329-43. PubMed ID: 25054392
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain.
    Mercadante S; Porzio G; Adile C; Aielli F; Cortegiani A; Dickenson A; Casuccio A
    Curr Med Res Opin; 2014 Oct; 30(10):2063-8. PubMed ID: 24926734
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Physiologically Based Pharmacokinetic Modeling to Supplement Nilotinib Pharmacokinetics and Confirm Dose Selection in Pediatric Patients.
    Heimbach T; Lin W; Hourcade-Potelleret F; Tian X; Combes FP; Horvath N; He H
    J Pharm Sci; 2019 Jun; 108(6):2191-2198. PubMed ID: 30721710
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Pharmacokinetic Study of Methylphenidate Hydrochloride Multilayer Extended-Release Capsules (Aptensio XR
    Adjei AL; Chaudhary I; Kollins SH; Padilla A
    Paediatr Drugs; 2020 Oct; 22(5):561-570. PubMed ID: 32776159
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of an integrated modelling and simulation approach to develop a simplified peginterferon alfa-2a dosing regimen for children with hepatitis C.
    Brennan BJ; Lemenuel-Diot A; Snoeck E; McKenna M; Solsky J; Wat C; Mallalieu NL
    Br J Clin Pharmacol; 2016 Apr; 81(4):658-66. PubMed ID: 26529640
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain.
    Frampton JE
    Drugs; 2010 Sep; 70(13):1719-43. PubMed ID: 20731478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.